

The Spectrum of β -thalassemia Mutations in Phitsanulok Province: Development of Multiplex ARMS for Mutation Detection

Saisiri Mirasena^{a,*}, Dawan Shimbhu^a, Mondhon Sanguansermisri^b
and Torpong Sanguansermisri^c

^aDepartment of Biochemistry, Faculty of Medical Science, Naresuan University, Phitsanulok 65000, Thailand.

^bDepartment of Pharmacy Practice, Faculty of Pharmaceutical Science, Naresuan University, Phitsanulok 65000, Thailand.

^cDepartment of Pediatrics, Faculty of Medicine, Chiang Mai University 50200, Thailand.

*Corresponding author. E-mail address: saisiri_m@hotmail.com (S. Mirasena)

Received 6 March 2007; accepted 26 April 2007

Abstract

Because many different mutations underline the β -thalassemia, they generate a wide variety of different clinical phenotypes. An understanding of the genotype is important for medical personnel to provide proper counseling to patients and their families. Characterization of these mutations should aid the planning of prenatal diagnosis program for β -thalassemia. The heterogeneity of the mutations makes it difficult and time consuming to identify the mutation in some individuals. We developed a single-tube multiplex amplification refractory mutation system (multiplex ARMS) to identify common ethnic-specific β -thalassemia mutations. Confirmation of multiplex ARMS results was carried out using direct sequencing. Three thousand three hundred and twenty-two people from Phitsanulok province were screened for β -thalassemia trait by quantitation of HbA₂ with microcolumn chromatography and characterized for the genotypes of mutations using multiplex ARMS and direct sequencing. We found that the deletion at codons 41/42 (-TCTT) was the most frequent (48%). Other mutations found in order of decreasing frequency were codon 17 (A→T) (30%), -28 (A→G) (6%) IVS-I-1(G→T) (6%), A-87 (C→A) (4%), IVS II-654 (C→T) (2%), codons 71/72 (+A) (2%) and codon 35 (C→A) (2%), respectively. These techniques were found to be a valuable tool for analysis of β -thalassemia mutations due to accurate, simple and speedy operation. An application for the diagnosis of severe thalassemia in high-risk pregnancies is promising.

Keywords: β -thalassemia; Multiplex ARMS; Thailand

Introduction

β -Thalassemia is the most common genetic disorder in Thailand. The prevalence of β -thalassemia gene carriers varies from 1 to 9% (Fucharoen & Winichagoon, 1987). There are more than 170 different β -thalassemia mutations characterized world-wide (Huisman & Carver, 1998). They generate a wide variety of different clinical phenotypes. The identification of the genotype is important for providing proper counseling to patients and their families. Characterization of these mutations should aid the planning of prenatal diagnosis program for β -thalassemia.

In Thailand, many molecular techniques have been employed for screening and diagnosis of β -thalassemia. Most of the molecular diagnostic laboratories utilize PCR amplification, with allele-specific amplification using an amplification refractory mutation system (ARMS) (Choopayak et al., 2003; Fucharoen et al., 1992; Fucharoen et al., 1995), allele-specific oligonucleotide probes (ASO) (Fucharoen et al., 1989; Laig et al., 1989; Laosombat et al., 1992; Nopparatana et al., 1995), or reverse dot-blot hybridization (Sutcharitchan et al., 1995; Winichagoon et al., 1999) to define the known mutations that cause β -thalassemia. However, for unknown mutations of the β -globin gene, single-strand confirmation polymorphism (SSCP) (Chinchang et al., 2005) and direct sequencing (Nopparatana et al., 1995; Sirichotiyakul et al., 2003) may be used. Recently, more sophisticated techniques such as real-time PCR and oligonucleotide microarray analysis have been described for the rapid analysis of thalassemia and hemoglobinopathies. However, these techniques are more laborious and expensive than current screening tests (Bhardwaj et al., 2003).

The ARMS technique is a simple PCR approach for β -thalassemia (Bhardwaj et al., 2005; Old et al., 1990; Varawalla et al., 1991). The ARMS protocol usually detects one mutation per reaction and can be laborious and expensive to use when looking for many common mutations individually in one sample. Our purpose was to establish a single-tube multiplex ARMS protocol to identify common β -globin gene mutations in Thailand.

More than 40 different β -globin gene mutations have been identified in the Thai population (Fucharoen et al., 1990; Fucharoen, Fuchareon, Jetsrisuparb et al., 1991; Fucharoen, Fuchareon, Laosombat et al., 1991; Fucharoen et al., 1989; Nopparatana et al., 1995; Nopparatana et al., 1999; Sanguansermisri et al., 1990; Thein et al., 1990; Winichagoon et al., 1990; Winichagoon et al., 1992) but only eight [codon 17 (A \rightarrow T), IVS I-1 (G \rightarrow T), codons 41/42 (-TCTT), codons 71/72 (+A), IVS I-5 (G \rightarrow C), IVS II-654 (C \rightarrow T), -87 (C \rightarrow A), -28 (A \rightarrow G)] that account for 99% of β -thalassemia in Thailand (Laosombat et al., 1992; Nopparatana et al., 1995; Sirichotiyakul et al., 2003; Sutcharitchan et al., 1995; Winichagoon et al., 1990). The multiplex ARMS was developed using two sets of ARMS primers. The first battery of multiplex ARMS has been established to identify the most common β -globin gene mutations including codon 17(A \rightarrow T), IVS I-1 (G \rightarrow T), codons 41/42 (-TCTT), and codons 71/72 (+A). The second set of multiplex ARMS was to identify other β -thalassemia mutations: -87 (C \rightarrow A), -28 (A \rightarrow G), IVS I-5 (G \rightarrow C), and IVS II-654 (C \rightarrow T). Each ARMS primer was designed to produce different amplified fragments that are easily differentiated in a single-tube reaction. Uncharacterized samples were further analyzed by direct sequencing. Mutations of the β -globin gene in all samples were confirmed by direct sequencing of the β -globin genes.

Materials and Methods

Subjects

We studied 3320 unrelated Thai subjects living in Phisanulok province who attended Thalassemia Research Unit at Naresuan University Hospital, Phisanulok, for thalassemia screening. After informed consent was obtained, 2 mL of peripheral blood samples were collected with EDTA as anticoagulant. All samples were screened for β -thalassemia with microcolumn chromatography on DEAE-Sephadex for quantitation of hemoglobin A₂. Fifty out of 3322 samples had HbA₂ concentrations between 3.5% and 9% and were considered β -thalassemia trait. The multiplex ARMS was developed using two sets of ARMS primers, one to identify the most common β -globin gene mutations including codon 17 (A \rightarrow T), IVS I-1 (G \rightarrow T), codons 41/42 (-TCTT), and codons 71/72 (+A), and the second to identify other β -thalassemia mutations: -87 (C \rightarrow A), -28 (A \rightarrow G), IVS I-5 (G \rightarrow C), and IVS II-654 (C \rightarrow T). Each ARMS primer was designed to produce different amplified fragments that easily differentiated the mutations in a single tube reaction.

Genomic DNA extraction

The fifty samples from those who had been diagnosed with β -thalassemia were further extracted for DNA with Chelex-100 method (Walsh et al., 1991). Briefly, 30 μ l of EDTA blood was added to 1 ml of 0.5% Triton X-100, mixed and centrifuged at 12 000 g for 1 min. the supernatant was removed and the pellet was washed with 1 ml of sterile water. Five percent chelex-100 suspension was added on top of the pellet, followed by 110 μ l of deionized sterile water. The solution was incubated at 56 °C for at least 2 hours and boiled for 10 minutes. The extracted genomic DNA was used as a template for multiplex ARMS and kept at 4 °C until β -globin gene analysis.

Primer design

Sixteen primers were designed according to the ARMS protocol for β -thalassemia mutations commonly found in Thai populations (Choopayak et al., 2003; Fucharoen & Fukumaki, 1992; Weatherall, 2001). Primers for -87 (C→A) and codons 71/72 were designed using a computer program, www.PrimerBiosoft.com. The genomic sequence of the β -globin gene was obtained from the GenBank database under the name HUMHBB, accession number U01317. The primer sequences were synthesized from Qiagen (Qiagen GmbH, Germany) and are shown in Figure 1 and Table 1.




Figure 1. Schematic diagram showing the β -globin genes and eight PCR fragments amplified for the multiplex ARMS assay. The β -globin gene is composed of three exons (grey boxes) and two introns (white boxes). Set I was the multiplex ARMS to identify the most common β -globin gene mutations [codon 17 (A→T), IVS I-1 (G→T), codons 41/42 (-TCTT), and codons 71/72 (+A)] and set II was the multiplex ARMS to identify other β -globin gene mutations [IVS I-5 (G→C), IVS II-654 (C→T), -87 (C→A), and -28 (A→G)] found in Thai population. Arrows indicated 5'→3' directions of the primer pair to identify each β -globin gene mutation.

Table 1. Primer sequences for the multiplex ARMS set I and II

Primer	Nucleotide sequence (5'→3')	Position ^a	Product size (bp)
ARMS Set I			
1A	CAATGTATCATGCCTCTTTGCACC	63224-63247	861
1B	GAGTCAAGGCTGAGAGATGCAGGA	64061-64084	
1C	ACCTCACCTGTGGAGCCAC	62028-62047	
Codon 17	CTCACCACTTCAGCCACGTTTCAGCTA	62238-62267	239
IVS I-1	TTAAACCTGTCTTGTAACCTTGATACCGAA	62279-62308	281
Codons 41/42	GAGTGACAGATCCCCAAAGGACTCAACCT	62441-62470	439
Codon 71/72 ^b	AGGTTGTCCAGGTGAGCCAGGCCATCAATT	62533-62562	535
ARMS Set II			
C	AGTGCTGCAAGAAGAACAACACTACC	35677-35700	326
D	CTCTGCATCATGGGCAGTGAGCTC	35981-36004	
F	CCCCTTCCTATGACATGAACTTAA	62680-62703	
G	ACCTCACCTGTGGAGCCAC	62028-62047	
H	GAGTCAAGGCTGAGAGATGCAGGA	64061-64084	
-87 ^b	CACTTAGACCTCACCTGTGGAGCCACACA	62021-62050	683
-28	AGGGAGGGCAGGAGCCAGGGCTGGGCTTAG	62080-62109	624
IVS I-5	CTCCTTAAACCTGTCTTGTAACCTTGTTAG	62312-62283	285
IVS II-654	GAATAACAGTGATAATTTCTGGGTTAACGT	63256-63285	829

^aPosition according to the GenBank accession number U01317.

^bThese sequences were designed by the software from www.PrimerBiosoft.com

These primers were coupled with one of the common primers depending on the location of the mutation in the β -globin gene and the direction of the allele-specific primer (Figure 1). A pair of control primers was also used as internal control for the PCR for all the mutations (A and B for the

multiplex ARMS set I, and C and D for set II). In set I, [codon 17 (A→T), IVS I-1 (G→T), codons 41/42 (-TCTT), and codons 71/72 (+A)], the four most common mutations, were amplified in a single reaction with the common primer E. For set II, oligonucleotide primers were designed for four mutations, namely, -87 (C→A), -28 (A→G), IVS I-5 (G→C), and IVS II-654 (C→T), were amplified in a single reaction with the common primers F, G, and H. These eight mutations account for 99% of mutations in Thailand.

Multiplex amplification refractory mutation system (Multiplex ARMS)

Each sample was initially screened for the most common mutations [codon 17 (A→T), IVS I-1 (G→T), codons 41/42 (-TCTT), and codons 71/72 (+A)]. If no mutation was detected, the sample was analyzed for other mutations reported in Thais [IVS I-5 (G→C), IVS II-654 (C→T), -87 (C→A), and -28 (A→G)]. The multiplex ARMS set I was carried out in a 25- μ l reaction containing 1x PCR buffer, 3.0 mM MgCl₂, 2.5 U HotStarTaq Polymerase (Qiagen GmbH, Germany), 200 μ M dNTPs, 200 pmol of each primer set, and 250 ng template DNA. After incubation at 95 °C for 15 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at 65 °C for 1 min and 72 °C for 1 min, with a final extension at 72 °C for 7 min. For the other β -thalassemia mutations the multiplex ARMS set II was performed with the same condition, except the primers set II was used instead. The PCR products were analyzed by electrophoresis on a 3% agarose gel containing ethidium bromide and were visualized by ultraviolet illumination. ARMS negative alleles were subjected to nucleotide sequencing of the PCR product.

Direct DNA sequencing

Two segments of the β -globin gene that covered all mutations previously characterized in Thai population were amplified with the primers previously described (Sirichotiyakul et al., 2003) The primers sequences are shown in Figure 2 and Table 2.




Figure 2. Schematic diagram showing the β -globin genes and two fragments amplified for the direct DNA sequencing. The β -globin gene is composed of three exons (grey boxes) and two introns (white boxes). Set I represents the primer pair that amplified exon I and II region and produced the fragments amplified sizes of 760 base pairs (bp). Set II represents the primer pair that amplified exon III region and produced the fragments amplified sizes of 690 bp.

Table 2. The sequences of primers used for the direct DNA sequencing

Primer	Nucleotide sequence (5'→3')	Position*	Product size (bp)
A	AGAAGAGCCAAGGACAGGTACG	61991-61990	760
B	TGCAATCATTCGTCTGTTTCCC	62730-62751	
C	TCCCTAATCTCTTTCTTTCAGG	63190-63211	660
D	TTTTCCCAAGGTTTGAAGTAGC	63829-63849	

*position according to the GenBank accession number U01317.

The reaction was carried out on a 25- μ l reaction mixture containing 1xPCR buffer, 2.5 mM MgCl₂, 1 U HotStarTaq Polymerase (Qiagen, Germany), 200 μ M dNTPs, 400 pmol primers, and 250 ng template DNA. The thermal cycling of set I consists of heating the reaction at

95 °C for 15 min and 40 cycles of denaturation at 94 °C for 45 sec, primer annealing at 60 °C for 1 min and DNA extension reaction at 72 °C for 2 min. The set II was performed like the set I condition except that the concentration of MgCl₂, and primers were 1.5 mM and 500 pmol, respectively. After heating the set II reaction at 95 °C for 15 min, 35 cycles was performed with denaturation for 45 sec at 94 °C, annealing for 1 min at 55 °C, and elongation for 90 sec at 72 °C.

Following gel electrophoresis to confirm successful amplification of the correct size product, the remaining PCR product was purified using a QIAquick PCR Purification Kit (Qiagen, Germany). Purified PCR products were sequenced using an ABI PRISM™ BigDye Terminator Cycle Sequencing Ready Reaction Kit protocol (Applied BioSystems, USA). Briefly, to a 0.2-ml PCR tube, 5-20 ng of DNA, 3.2 pmol of sequencing primer, 8 µl Terminator Ready Reaction Mix were added and made up to a final volume of 10 µl with deionized distilled water. The sequencing products were cycled in a thermal cycler for 25 cycles of 96 °C for 10 sec, 50 °C for 5 sec and 60 °C for 4 min.

The extension products were precipitated using ethanol and sodium acetate. To the sequencing reaction, 2 µl of 3M sodium acetate, pH 4.6, 50 µl of 95% ethanol were added and left at room temperature for ≥ 15 min but not overnight. Samples were centrifuged at 12 000 g for 20 min and the supernatant was removed and discarded. To the pellet, 250 µl of 70% ethanol was added and briefly vortexed. After centrifugation for 5 min at 12 000 g, the supernatant was dried for 1 min at 90 °C with a heat block

Samples were analyzed on an automated sequencer, ABI PRISM 310 Genetic Analyzer (Applied Biosystems, USA) as per the manufacturer's instructions.

Results

We have developed the multiplex ARMS to identify the eight most common β-thalassemia mutations in Thai population and standardized on DNA samples with known mutation, the pattern being shown in Figure 3. The method was subsequently tested on 50 unrelated samples with unknown β-thalassemia mutations (Figure 4). Internal control bands were also amplified in all of the reactions, indicating successful PCR. No band other than the internal control was amplified in the negative control reaction, which was carried out with a normal blood for β-thalassemia (Figure 4). The codons 41/42 (-TCTT) mutation is the most common β-thalassemia defect in Thai population. The following mutations are presented in decreasing frequency: codon 17 (A→T), -28 (A→G), IVS I-1 (G→T), -87 (C→A), codons 71/72 (+A), IVS II-654 (C→T), and codon 35 (C→A) (Table 3).

Figure 5 shows the sequencing of the β-thalassemia mutations found in Phitsanulok. We were unable to determine the mutation in one sample with multiplex ARMS. Genomic sequencing revealed this mutation was codon 35 (C→A) (Figure 5F). The primer for this mutation was not used in our multiplex ARMS condition because this mutation was less common in the north. Thus by using the multiplex ARMS along with sequencing, it is possible to detect all of the mutations. The strategy presented here for characterization of unknown mutations is quite simple and cost effective.




Figure 3. Multiplex ARMS patterns of eight common β -globin gene mutations in a 3% agarose gel. Lane 1-4, 861-bp an internal control for multiplex ARMS set I; lane 1, 281-bp of IVS I-I (G \rightarrow T); lane 2, 535-bp of codons 71/72 (+A); lane 3, 241-bp of codon 17 (A \rightarrow T); lane 4, 454-bp of codons 41/42 (-TCTT). Lane 5-8, 326-bp an internal control for multiplex ARMS set II; lane 5, 258-bp of IVS I-5 (G \rightarrow C); lane 6, 624-bp of -28 (A \rightarrow G); lane 7, 829-bp of IVS II-654 (C \rightarrow T); lane 8, 683-bp of -87 (C \rightarrow A); M (marker), 100 base pairs DNA ladder (Promega, USA).




Figure 4. Results of multiplex ARMS for the most common β -thalassemia mutations found in Thai population. (A) The multiplex ARMS set I; M (marker), 100 base pairs DNA ladder (Promega, USA); the 861-bp band is the β -globin fragment used as an internal control. Lane 1 and 2 were the codon 17 (A \rightarrow T) (241-bp); lane 3, 4, 6, 8, 9, and 10 were the codons 41/42 (-TCTT) (454-bp); lane 5 was the codons 71/72 (+A) (535-bp); lane 7 was the IVS I-I (G \rightarrow T) (281-bp); lane 11 was the negative control. (B) The multiplex ARMS set II; M (marker), 100 base pairs DNA ladder; the 326-bp band is the β -globin fragment used as an internal control. Lane 1, 2 and 3 were -28 (A \rightarrow G) (624-bp); lane 4 and 5 were -87 (C \rightarrow A) (683-bp); lane 6 was IVS II-654 (C \rightarrow T) (829-bp); lane 7 is the negative control.

Discussion

β -Thalassemia is the most common genetic disorders in Thailand. A previous report investigated the distribution of β -thalassemia mutations in this area, this report was based on the analysis of a fairly small number of subjects (Choopayak et al., 2003). In the present study we described a wider spectrum of β -thalassemia mutations in Phitsanulok by analyzing 50 β -globin chromosomes. Eight different β -thalassemia mutations were identified in our study accounted for more than 99% of all the β -thalassemia chromosomes. These included four of the common Thai mutations: codons 41/42, codon 17, IVS I-1, and codons 71/72. In the current study, 24 chromosomes were found carrying the codons 41/42 mutation, representing 48% of the total Thai β -thalassemic chromosomes. When compared to other areas of Thailand (Table 3), the

distribution and types of β -thalassemia mutations in Phitsanulok were found to be generally similar; a small number of mutations predominated and the most common ones were geographically the most widespread and theoretically the oldest.

Table 3. Distribution of β -thalassemia in Thailand*

Mutations	Central		South		Northeast		North	
	No.	%	No.	%	No.	%	No.	%
β^0-thalassemia								
Codons 41/42 (-TCTT)	156	41.6	85	30.1	19	31.6	45	39.8
Codon 17 (A→T)	62	16.5	32	11.4	13	21.7	45	39.8
Codon 35 (C→A)	7	1.9	0	0	0	0	ND	-
IVS-I-1 (G→T)	5	1.3	17	6.0	1	1.7	ND	-
Codons 71/72 (+A)	8	2.1	0	0	8	13.3	ND	-
Codons 8/9 (+G)	ND	-	1	0.3	ND	-	ND	-
Codons 14/15 (+G)	1	0.3	ND	-	ND	-	ND	-
Codon 15 (-T)	1	0.3	0	0	ND	-	ND	-
Codon 26 (G→T)	ND	-	ND	-	1	1.7	ND	-
Codons 27/28 (+C)	2	0.5	ND	-	ND	-	ND	-
Codon 41 (-C)	2	0.5	4	1.4	ND	-	ND	-
Codon 43 (G→T)	2	0.5	0	0	ND	-	ND	-
Codon 95 (+A)	1	0.3	ND	-	ND	-	ND	-
3.4 kb deletion	1	0.3	12	4.3	0	0	1	0.9
619 bp deletion	5	1.3	ND	-	0	0	ND	-
105 bp deletion	ND	-	1	0.3	ND	-	ND	-
β^+-thalassemia								
-86 (C→G)	1	0.3	ND	-	ND	-	ND	-
-28 (A→G)	35	9.3	16	5.7	1	1.7	4	3.5
Codon 19 (A→G)	11	2.9	43	15.3	0	0	ND	-
IVS-I-5 (G→C)	16	4.3	53	18.8	0	0	2	1.8
IVS-II-654 (C→T)	28	7.5	6	2.1	5	8.3	1	0.9
Codon 26 (HbE)	2	0.5	ND	-	9	15.0	ND	-
Unknown	29	7.8	12	4.3		5.0	15	13.3
Total	375		282		60		113	

*from Winichagoon et al., 1995

ND = not determined

The most common mutation was the codons 41/42 and this was the same finding observed in Thailand (Fucharoen et al., 1989; Laig et al., 1989; Laosombat et al., 1992; Nopparatana et al., 1995; Sirichotiyakul et al., 2003; Sutcharitchan et al., 1995; Weatherall, 2001; Winichagoon et al., 1995; Winichagoon et al., 1999). The second most common mutation was codon 17, similar to the central (Winichagoon et al., 1995; Winichagoon et al., 1999), north (Sirichotiyakul et al., 2003) and northeast (Fucharoen & Fukumaki, 1992; Fucharoen et al., 1989), whereas IVS I-5 was the second most common mutation observed in the south (Laosombat et al., 1992; Nopparatana et al., 1995). The frequency of IVS I-1 was similar to the north (Sirichotiyakul et al., 2003), and -28 was similar to the central (Winichagoon et al., 1995), whereas codon 19 was the third most common mutation in the south (Laosombat et al., 1992; Nopparatana et al., 1995; Winichagoon et al., 1995). Furthermore, the mutations -87, codons 71/72, and IVS II-654 were similar to the north (Sirichotiyakul et al., 2003), while codon 35 was similar to the central (Winichagoon et al., 1995; Winichagoon et al., 1999).




Figure 5. Nucleotide sequence chromatograms of the β -globin genes. (A) The forward sequence of a substitution in -87 (C \rightarrow A); (B) The forward sequence of a substitution in -28 (A \rightarrow G); (C) The forward sequence of a substitution in codon 17 (A \rightarrow T); (D) The forward sequence of a 4 bp deletion of codons 41/42 (-TCTT); (E) The forward sequence of a addition in codons 71/72 (+A); (F) The forward sequence of a substitution in codon 35 (C \rightarrow A); (G) The forward sequence of a substitution in IVS I-1 (G \rightarrow T); and (H) The reverse complementary sequence of a substitution in IVS II-654 (C \rightarrow T).

When the percentage of the eight most common β -thalassemia mutations in the population of Phitsanulok is compared with the overall frequency of mutations in the country, some interesting differences are revealed. Increased percentage of the mutations -28, -87, and decreased percentage of codons 71/72 were observed compared to the North (Sirichotiyakul et al., 2003). The IVS I-5 mutation which is frequent in the central and south, was absent in the samples from Phitsanulok.

Our aim was to establish multiplex ARMS to detect eight common β -thalassemia mutations in Thailand since this technique reduces the overall cost and time. Multiplex ARMS relies on the principle that oligonucleotides with mismatched terminal 3'-nucleotides will not function as primers in a PCR under appropriate conditions. As a result, DNA amplification does not occur.

We found that the most important factor for reliable and accurate results using multiplex ARMS was the primer concentration. Polymerase chain reactions were carried out in 25- μ l volume with primer concentrations of not more than 200 pmol. Increase in the primer concentrations led to non-specific DNA amplifications of the same molecular weight, although these non-specific DNA bands were less distinct compared with the specific amplified bands.

The PCR conditions for denaturation (95 °C), annealing (65 °C), and synthesis (72 °C) were the same for all the mutations studied. Detection of amplified DNA in our multiplex ARMS protocol was clearly observed on 3 percent agarose gel and there was no need to use the more expensive NuSieve agarose gels. In addition, we were able to lower the concentration of enzyme Taq polymerase to 0.5 U per PCR. The cost per analysis using multiplex ARMS compared with sequencing is also greatly reduced.

The ARMS technique used in this study allowed precise identification of the mutations in all samples, making detection easy, straightforward and less time consuming with 100% accuracy. The use of the multiplex ARMS technique saved both time and cost with 100% accuracy. From the economical point of view, reduced labor time and use of a simpler equipment decrease the cost of test per sample by the multiplex ARMS.

In Thailand, with its vast spectrum of β -thalassemia mutations, a procedure such as multiplex ARMS is much more efficient and practical than single ARMS because as many as β -thalassemia mutations can be simultaneously screened on a single reaction in a reasonably short time. This number can be increased by designing a second set to be run in parallel, i.e. 10 mutations on 2 reactions.

Conclusion

In conclusion, the multiplex ARMS protocol described in this study has permitted an accurate, rapid, inexpensive, and direct diagnosis technique for β -thalassemia. Multiplex ARMS and sequencing would provide rapid screening for β -thalassemia mutations in Thailand. Furthermore, the detailed distribution tables of β -thalassemia mutations are essential for counseling and extraction of genetic diversity estimates for similar studies in other inherited disorders.

References

- Bhardwaj, U., Zhang, Y. H., Lorey, F., McCabe, L. L., & McCabe, E. R. (2005). Molecular genetic confirmatory testing from newborn screening samples for the common African-American, Asian Indian, Southeast Asian, and Chinese beta-thalassemia mutations. *American Journal of Hematology*, 78, 249-255.
- Bhardwaj, U., Zhang, Y. H., & McCabe, E. R. (2003). Neonatal hemoglobinopathy screening: Molecular genetic technologies. *Molecular Genetic Metabolism*, 80, 129-137.
- Chinchang, W., Viprakasit, V., Pung-Amritt, P., Tanphaichitr, V. S., & Yenchitsomanus, P. T. (2005). Molecular analysis of unknown beta-globin gene mutations using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and its application in Thai families with beta-thalassemias and beta-globin variants. *Clinical Biochemistry*, 38, 987-996.

- Choopayak, C., Limmonkon, A., Suyasanant, U., & Pongbangpho, S. (2003). PCR detection of α -thalassemia 1 (Southeast Asian type) carriers in the south northern Thailand. *Naresuan University Journal*, 11(2), 29-36.
- Fucharoen, S. F., Fucharoen, G., & Fukumaki, Y. (1992, November). *A multiplex allele specific polymerase chain reaction (MAS-PCR) for non-radioactive detection of common β -thalassemia genes in the Asian population*. At the conference on the 6th Federation of Asian and Oceanian Biochemist [FAOB] Congress: Biochemistry 1992, China.
- Fucharoen, G., Fucharoen, S., Jetsrisuparb, A., & Fukumaki, Y. (1990). Molecular basis of HbE-beta-thalassemia and the origin of HbE in northeast Thailand: identification of one novel mutation using amplified DNA from buffy coat specimens. *Biochemical and Biophysical Research Communications*, 170, 698-704.
- Fucharoen, G., Fuchareon, S., Jetsrisuparb, A., & Fukumaki, Y. (1991). Eight-base deletion in exon 3 of the beta-globin gene produced a novel variant (beta khon kaen) with an inclusion body beta-thalassemia trait. *Blood*, 78, 537-539.
- Fucharoen, S., Fucharoen, G., Laosombat, V., & Fukumaki, Y. (1991). Double heterozygosity of the beta-Malay and a novel beta-thalassemia gene in a Thai patient. *American Journal of Hematology*, 38, 142-144.
- Fucharoen, S., Fucharoen, G., Ratanasiri, T., Jetsrisuparb, A., & Fukumaki, Y. (1995). A simple non radioactive method for detecting beta-thalassemia/hbe disease: application to prenatal diagnosis. *The Southeast Asian Journal of Tropical Medicine and Public Health*, 26(Suppl. 1), 278-281.
- Fucharoen, S., Fucharoen, G., Sriroongrueng, W., Laosombat, V., Jetsrisuparb, A., Prasatkaew, S., et al. (1989). Molecular basis of beta-thalassemia in Thailand: Analysis of beta-thalassemia mutations using the polymerase chain reaction. *Human Genetics*, 84, 41-46.
- Fucharoen, S., & Winichagoon, P. (1987). Hemoglobinopathies in Southeast Asia. *Hemoglobin*, 11, 65-88.
- Huisman, T. H., & Carver, M. F. (1998). The beta- and delta-thalassemia repository. *Hemoglobin*, 22, 169-195.
- Laig, M., Sanguansermisri, T., Wiangnon, S., Hundrieser, J., Pape, M., & Flatz, G. (1989). The spectrum of beta-thalassemia mutations in northern and northeastern Thailand. *Human Genetic*, 84, 47-50.
- Laosombat, V., Fucharoen, S. P., Panich, V., Fucharoen, G., Wongchanchailert, M., Sriroongrueng, W., et al. (1992). Molecular basis of beta thalassemia in the south of Thailand. *American Journal of Hematology*, 41, 194-198.
- Nopparatana, C., Panich, V., Saechan, V., Sriroongrueng, V., Rungjeadpha, J., Pornpatkul, M., et al. (1995). The spectrum of beta-thalassemia mutations in southern Thailand. *The Southeast Asian Journal of Tropical Medicine and Public Health*, 26(Suppl.1), 229-234.
- Nopparatana, C., Saechan, V., Pornpatkul, M., Panich, V., & Fukumaki, Y. (1999). A novel 105 basepair deletion causing beta(0)-thalassemia in members of a Thai family. *American Journal of Hematology*, 61, 1-4.
- Old, J. M., Varawalla, N. Y., & Weatherall, D. J. (1990). Rapid detection and prenatal diagnosis of beta-thalassaemia: studies in Indian and Cypriot populations in the UK. *Lancet*, 336, 834-837.
- Rust, S., Funke, H., & Assmann, G. (1993). Mutagenically separated PCR (MS-PCR): A highly specific one step procedure for easy mutation detection. *Nucleic Acids Research*, 21, 3623-3629.

- Sanguanserm Sri, T., Pape, M., Laig, M., Hundrieser, J., & Flatz, G. (1990). Beta zero-thalassemia in a Thai family is caused by a 3.4 kb deletion including the entire beta-globin gene. *Hemoglobin*, 14, 157-168.
- Sirichotiyakul, S., Saetung, R., & Sanguanserm Sri, T. (2003). Analysis of beta-thalassemia mutations in northern Thailand using an automated fluorescence DNA sequencing technique. *Hemoglobin*, 27, 89-95.
- Sutcharitchan, P., Saiki, R., Fucharoen, S., Winichagoon, P., Erlich, H., & Embury, S. H. (1995). Reverse dot-blot detection of Thai beta-thalassaemia mutations. *British Journal of Haematology*, 90, 809-816.
- Thein, S. L., Winichagoon, P., Hesketh, C., Best, S., Fucharoen, S., Wasi, P., et al. (1990). The molecular basis of beta-thalassemia in Thailand: Application to prenatal diagnosis. *The American Journal of Human Genetics*, 47, 369-375.
- Varawalla, N. Y., Old, J. M., Sarkar, R., Venkatesan, R., & Weatherall, D. J. (1991). The spectrum of beta-thalassaemia mutations on the Indian subcontinent: the basis for prenatal diagnosis. *British Journal of Haematology*, 78, 242-247.
- Walsh, P.S., Metzger, D.A., & Higuchi, R. (1991). Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. *Biotechniques*, 10, 506-513.
- Weatherall, D. J., Clegg, J. B. (2001). *The Thalassemia syndromes* (4th ed.). Oxford: Blackwell Science.
- Winichagoon, P., Fucharoen, S., Thonglairoam, V., Tanapotiwirot, V., & Wasi, P. (1990). Beta-thalassemia in Thailand. *Annals of the New York Academy of Sciences*, 612, 31-42.
- Winichagoon, P., Fucharoen, S., Wilairat, P., Chihara, K., Fukumaki, Y., & Wasi, P. (1992). Identification of five rare mutations including a novel frameshift mutation causing beta zero-thalassemia in Thai patients with beta zero-thalassemia/hemoglobin E disease. *Biochimica and Biophysica Acta*, 1139, 280-286.
- Winichagoon, P., Fucharoen, S., Wilairat, P., & Fukumaki, Y. (1995). Molecular mechanisms of thalassemia in southeast Asia. *The Southeast Asian Journal of Tropical Medicine and Public Health*, 26 (Suppl. 1), 235-240.
- Winichagoon, P., Saechan, V., Sripanich, R., Nopparatana, C., Kanokpongsakdi, S., Maggio, A., et al. (1999). Prenatal diagnosis of beta-thalassaemia by reverse dot-blot hybridization. *Prenatal Diagnosis*, 19, 428-435.
- Wong, W. S., Chan, A. Y., Yip, S. F., & Ma, E. S. (2004). Thalassemia intermedia due to co-inheritance of beta0/beta(+)-thalassemia and (- -SEA) alpha-thalassemia/Hb Westmead [alpha122(H5)His > Gln (alpha2)] in a Chinese family. *Hemoglobin*, 28, 151-156.
- Wu, D. Y., Ugozzoli, L., Pal, B. K., & Wallace, R. B. (1989). Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. *Proceedings of the National Academy of Sciences USA*, 86, 2757-2760.